NCT04651777 - Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 8, 2022

Primary Completion Date

August 25, 2023

Study Completion Date

December 31, 2025

Conditions

Asthma

Interventions

DRUG

FF/UMEC/VI

The investigational drug is a single Ellipta inhaler containing 200 ug fluticasone furoate, 62.5 ug umedlidinium and 25 ug vilanterol. The drug is delivered in an Ellipta inhaler in a single dose once daily.

Trial Locations (1)

N6A 5B7

Robarts Research Institute; The University of Western Ontario; London Health Sciences Centre, London